CompletedNCT00137020
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Alexandria and 26 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNovember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 294
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Egypt, Greece, Jordan, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00137020
- Official title
Show the full official title
A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder
Recruitment & locations
CompletedAlexandria, Egypt · Asyut, Egypt · Cairo, Egypt
22 more locations
- Tanta, Egypt
- Larissa, Greece
- Athens, Greece
- Jordan, Jordan
- Kuwait City, Kuwait
- Beirut, Lebanon
- Khobar, Saudi Arabia
- Garankuwa, South Africa
- Krugersdorp, South Africa
- Noordheuwel, Krugersdorp, South Africa
- Bellair, Durban, South Africa
- Pinetown, Durban, South Africa
- Observatory, Cape Town, South Africa
- Ankara, Türkiye
- Bursa, Türkiye
- Erzurum, Türkiye
- Istanbul, Türkiye
- Izmir, Türkiye
- Manisa, Türkiye
- Şişli, Türkiye
- Dubai, United Arab Emirates
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including ziprasidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...